Second Consecutive Year DUSA Has Been Recognized
WILMINGTON, Mass., Oct. 21 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.
"DUSA is pleased to receive this elite recognition from Deloitte for the second year in a row," said Bob Doman, DUSA's President and Chief Executive Officer. "Despite the current economic environment, clinicians continue to embrace Levulan(R) Photodynamic Therapy (PDT) based on its clinical efficacy and patient satisfaction in the treatment of actinic keratoses (AKs)."
Levulan PDT, one of the fastest growing procedures in dermatology, is currently approved for the treatment of Grade 1 and 2 AKs of the face and scalp. AKs are the most frequently diagnosed skin disease by U.S. dermatologists with over 5M treatment visits per year. Through the first six months of 2009, U.S. PDT revenue grew 22%. DUSA is also in clinical development of its Levulan PDT technology platform for the treatment of AKs and the prevention of squamous cell carcinomas in chronically immunosuppressed solid organ transplant recipients.
Technology Fast 500 Selection and Qualifying Criteria
Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Technology Fast 500 website, and public company database research conducted by Deloitte LLP. Technology Fast 500 award winners for 2009 are selected based on percentage fiscal year revenue growth during the five year period from 2004 to 2008.
To be considered, Technology Fast 500 entrants must meet the following criteria:
The complete 2009 Deloitte Technology Fast 500 report is available online: http://www.deloitte.com/view/en_US/us/Industries/Technology/technologyfast500/index.htm.
About Actinic Keratoses
Actinic keratoses are rough-textured, dry, scaly patches on the skin caused by excessive exposure to ultraviolet light, such as sunlight. They occur most frequently on sun exposed areas such as the face, scalp, ears, neck, hands and arms. They form on the outermost layer of skin and they can range in color from skin toned to reddish brown. They can also range in size from as small as a pinhead to larger than a quarter.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc.(R)( )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(R). DUSA is researching Levulan PDT for the treatment of AKs and the reduction of new non-melanoma skin cancer in chronically immunosuppressed solids organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.
As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.
SOURCE DUSA Pharmaceuticals, Inc.
|SOURCE DUSA Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved